巴曲酶联合低分子肝素治疗老年下肢深静脉血栓的临床疗效  

Clinical efficacy of batroxobin combined with low molecular weight heparin in the treatment of deep vein thrombosis of lower extremity in elderly patients

作　　者：苏苗苗 张宇[1] 吴继东[1] 李新宇[1] Su Miaomiao;Zhang Yu;Wu Jidong;Li Xinyu(Department of Vascular Surgery,Beijing Aerospace General Hospital,Beijing 100076,China)

机构地区：[1]北京航天总医院血管外科,北京100076

出　　处：《血管与腔内血管外科杂志》2025年第2期217-221,共5页Journal of Vascular and Endovascular Surgery

摘　　要：目的探讨巴曲酶联合低分子肝素对老年下肢深静脉血栓(DVT)的治疗效果和安全性。方法收集2020年1月至2023年1月北京航天总医院收治的83例老年下肢DVT患者的临床资料,按照治疗方法的不同将其分为对照组(n=39,在常规治疗基础上采用低分子肝素治疗)和观察组(n=44,在对照组基础上采用巴曲酶)。比较两组患者的临床疗效、凝血功能相关指标及并发症发生情况。结果观察组患者总有效率为90.90%(40/44),高于对照组患者的74.35%(29/39),差异有统计学意义(P﹤0.05)。治疗后,两组患者活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)及凝血酶时间(TT)、血纤维蛋白原(FIB)均小于本组治疗前,且观察组患者凝血功能各指标均小于对照组患者,差异均有统计学意义(P﹤0.05)。两组患者并发症总发生率比较,差异无统计学意义(P﹥0.05)。结论巴曲酶联合低分子肝素治疗老年下肢DVT患者的临床效果显著,明显改善了患者的凝血功能,安全性较高。Objective To investigate the efficacy and safety of batroxobin combined with low molecular weight heparin in the treatment of deep vein thrombosis(DVT)of lower extremity in elderly patients.Method Clinical data of 83 elderly patients with DVT of lower extremity treated in Beijing Aerospace General Hospital from January 2020 to January 2023 were collected.According to different treatment methods,they were divided into control group(n=39,low molecular weight heparin in addition to conventional treatment)and observation group(n=44,batroxobin in addition to control group).The clinical efficacy,coagulation function related indexes and complications were compared between the two groups.Result The total effective rate of observation group was 90.90%(40/44),which was higher than that of control group 74.35%(29/39),the difference was statistically significant(P<0.05).After treatment,activated partial thromboplastin time(APTT),prothrombin time(PT),thrombin time(TT)and fibrinogen(FIB)in two groups were all lower than before treatment,and all indexes of coagulation function in observation group were lower than those in control group,with statistical significance(P<0.05).There was no significant difference in the total incidence of complications between the two groups(P>0.05).Conclusion Batroxobin combined with low molecular weight heparin in the treatment of elderly patients with DVT lower extremity has significant clinical effect,and significantly improves the coagulation function of patients with high safety.

关 键 词：巴曲酶 低分子肝素 下肢深静脉血栓 

分 类 号：R543[医药卫生—心血管疾病]